<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056195</url>
  </required_header>
  <id_info>
    <org_study_id>OSCO-P2101</org_study_id>
    <nct_id>NCT04056195</nct_id>
  </id_info>
  <brief_title>Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oscotec Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oscotec Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study in patients with persistent and chronic Immune Thrombocytopenia (ITP), who have failed&#xD;
      to respond or relapsed after prior therapy, with a platelet count &lt;30,000/µL. Patient will be&#xD;
      randomly assigned in 2 groups with two dose levels of SKI-O-703 200mg BID, 400 mg BID, and&#xD;
      placebo; administered orally twice a day.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the efficacy, safety, tolerability,pharmacokinetics (PK), and&#xD;
      pharmacodynamics (PD) of select (200 mg BID and 400 mg BID) doses of SKI-O-703 in persistent&#xD;
      and chronic ITP patients who have failed to respond or relapsed after prior therapy, with a&#xD;
      platelet count &lt;30,000/µL. on 2 occasions at least 7 days apart with the confirmatory count&#xD;
      on the first day of treatment.&#xD;
&#xD;
      subjects will participate in 3 treatment groups (24 subjects in each of the active treatment&#xD;
      groups and 12 subjects in the placebo group). The total study duration will be 20 weeks per&#xD;
      subject, which consists of up to 4 weeks of screening period, 12 weeks of treatment period,&#xD;
      and 4 weeks of follow-up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Response</measure>
    <time_frame>Up to week 12</time_frame>
    <description>Platelet count &gt;= 30,000/µL and doubling the baseline (average of 2 previous counts)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs leading to Discontinuation</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with vital sign abnormalities</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with 12-lead electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with physical examination abnormalities</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinical laboratory abnormalities</measure>
    <time_frame>Up to week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding score</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Measured by Immune thrombocytopenic purpura (ITP) bleeding score (Br. J. Haematol 2007;138(2): 245-8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life score</measure>
    <time_frame>Up to week 16</time_frame>
    <description>Measured by the SF-36 score</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 capsules of 100 mg SKI-O-703 BID (twice a day) 12 hours apart + 2 capsules of placebo during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 capsules of 100 mg SKI-O-703 + 0 capsules of placebo during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 capsules of placebo during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKI-O-703</intervention_name>
    <description>The SKI-O-703 capsules will contain 100 mg of drug substance.</description>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo capsules are filled with microcrystalline cellulose.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary ITP (persistent or chronic)&#xD;
&#xD;
          -  Failed to respond or relapsed after at least 1 prior therapy, with a platelet count of&#xD;
             &lt;30,000/µL on 2 occasions at least 7 days apart with the confirmatory count on the&#xD;
             first day of treatment&#xD;
&#xD;
          -  Adequate hematologic, hepatic, and renal function&#xD;
&#xD;
          -  ECOG performance status of 0, 1, or 2&#xD;
&#xD;
          -  Male and female subjects, the subject and their partners of childbearing potential&#xD;
             agree to use medically acceptable methods of contraception during the study and for 6&#xD;
             months following discontinuation of study drug (excluding women who are not of&#xD;
             childbearing potential and men who have been sterilized. Men who have been sterilized&#xD;
             should be confirmed to have negative sperm count on 2 consecutive occasions.)&#xD;
&#xD;
          -  Male subjects agree not to donate sperm for 90 days after the last dose of study drug&#xD;
&#xD;
          -  Female subjects have negative pregnancy tests at Screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of current, active malignancy requiring or likely to require chemotherapeutic&#xD;
             or surgical treatment during the study, with the exception of non-melanoma skin&#xD;
             cancer, carcinoma in situ of the cervix, and localized prostate cancer managed by&#xD;
             active surveillance&#xD;
&#xD;
          -  Transfusion with blood or blood products or plasmapheresis within 2 weeks before the&#xD;
             first administration of study drug&#xD;
&#xD;
          -  History of known inherited coagulopathy, or recent arterial or deep venous thrombosis&#xD;
             within the preceding 6 months&#xD;
&#xD;
          -  Change in corticosteroid or immunosuppressant dose within 2 weeks prior to Day 1&#xD;
&#xD;
          -  Treatment with thrombopoietin receptor agonists within 2 weeks before Day 1&#xD;
&#xD;
          -  Treatment with rituximab or splenectomy within the 8 weeks prior to Day 1&#xD;
&#xD;
          -  Treatment with intravenous immunoglobulins (IVIGs) within 4 weeks prior to Day 1&#xD;
&#xD;
          -  Acute infection requiring oral antibiotics within 2 weeks&#xD;
&#xD;
          -  Infections requiring intravenous antibiotics or hospitalization within 3 months&#xD;
&#xD;
          -  Positive test results at Screening for human immunodeficiency virus, hepatitis B&#xD;
             surface antigen, or hepatitis C virus antibody or positive result for hepatitis B core&#xD;
             antibody with a negative result for hepatitis B surface antigen&#xD;
&#xD;
          -  Received live vaccine within 28 days prior to Day 1 or plan to receive one during the&#xD;
             study&#xD;
&#xD;
          -  History or presence of any gastrointestinal, hepatic, or renal disease or any other&#xD;
             condition known to interfere with the absorption, distribution, metabolism, or&#xD;
             excretion of drugs&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Subject had 12-lead electrocardiogram (ECG) findings of corrected QT interval by&#xD;
             Fridericia formula (QTcF) &gt; 450 msec (males) or &gt; 470 msec (females), cardiac&#xD;
             arrhythmias, or clinically significant cardiac or ECG abnormalities&#xD;
&#xD;
          -  Subject received any investigational medication within 30 days or 5 half-lives -&#xD;
             Concomitant use of any anticoagulants and platelet aggregation inhibiting drugs&#xD;
             including aspirin (within 14 days of planned dosing through end of follow-up)&#xD;
&#xD;
          -  Female subject who is currently pregnant or breastfeeding&#xD;
&#xD;
          -  Prior treatment with a SYK inhibitor&#xD;
&#xD;
          -  Planned surgery in the time frame of the dosing period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information</last_name>
    <phone>please email</phone>
    <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain the NCT# and Site#</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California, 1441 Eastlake Ave.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center, 2301 Erwin Road</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>22705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>East Carolina University, 600 Moye Boulevard</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation, 9500 Euclid Avenue</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras, Department of Internal Medicine, Hematology Division, Rio Patra</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Laiko General Hsoptial of Athens, 16 Sevastoupoleos Street</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11526</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa, Mezourlo</name>
      <address>
        <city>Larissa</city>
        <zip>41110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AHEPA University General Hospital of Thessaloniki, Kyriakidi Stilponos 1</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital, Konstantinoupoleos 49</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Georgios Papanikolaou General Hospital of Thessaloniki, Exohi</name>
      <address>
        <city>Thessaloníki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital, 164 World Cup-ro, Yeongtong-gu</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggido</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center - PPDS, 88 Olympic-ro 43-gil, Songpa-gu</name>
      <address>
        <city>Seoul</city>
        <zip>5505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClincialTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center PPDS, 81 Irwon-dong Gangnam-gu</name>
      <address>
        <city>Seoul</city>
        <zip>6351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital, 101 Daehak-ro, Jongno-gu</name>
      <address>
        <city>Soeul</city>
        <zip>3080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrials.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System, 50-1 Yonsei-Ro, Seodaemun-Gu</name>
      <address>
        <city>Soeul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy, Ujejskiego 75</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne, Klinika Hematologii i Transplantologii, Smoluchowskiego 17</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Copernicus PL Sp. z o.o. Wojewodzkie Centrum Onkologii, Aleja Zwyciestwa 31/32</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>EMC Instytut Medyczny S.A Przychondnia przy Łowieckiej, Łowiecka</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quironsalud Madrid, Calle Diego De Velazquez 1</name>
      <address>
        <city>Pozuelo De Alarcón</city>
        <state>Madrid</state>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal, Carretera de Colmenar Viejo Km. 9100</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre, Avenida de Cordoba, s/n</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz, Paseo Castellana 261</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hosptial Regional Universitario de Malaga - Hospital General, Avenida Carlos Haya, s/n</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Complejo Asistencial Universitario de Salamanca - H. Clinico, Paseo de San Vincent, 58</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio, Avenida Manuel Siurot, Centro de Diagnostico y Tratamiento</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia, Avda Fernando Abril Martorell no° 106</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and NCT 04056195 in subject line of email and send to</last_name>
      <email>OSCOP2101ClinicalTrial.sm@ppdi.com</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/Recalls/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 12, 2019</study_first_submitted>
  <study_first_submitted_qc>August 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

